Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Interest of a Long-Term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-Responder Chronic Hepatitis C Patients

Trial Profile

Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Interest of a Long-Term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-Responder Chronic Hepatitis C Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 May 2014 Status changed from recruiting to completed.
    • 09 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 09 Apr 2014 Primary endpoint 'Fibrosis-measures' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top